Treatment of Patients with Advanced Solid Tumors with Oral Agent ORIN1001 and in Combination with Standard of Care.
- First Posted Date
- 2021-12-13
- Last Posted Date
- 2024-12-31
- Lead Sponsor
- Orinove, Inc.
- Target Recruit Count
- 150
- Registration Number
- NCT05154201
- Locations
- 🇨🇳
Shandong Provincial Cancer Hospital, Shandong, China
🇨🇳Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳Jilin Cancer Hospital, Changchun, China
Evaluation of Oral ORIN1001 in Subjects with Idiopathic Pulmonary Fibrosis (IPF)
- First Posted Date
- 2020-11-25
- Last Posted Date
- 2024-12-31
- Lead Sponsor
- Orinove, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT04643769
- Locations
- 🇺🇸
Duke University Hospital, Durham, North Carolina, United States
🇺🇸Loyola University Medical Center, Maywood, Illinois, United States
🇺🇸Mayo Clinic Hospital, Jacksonville, Florida, United States
ORIN1001 in Patients with Advanced Solid Tumors and Relapsed Refractory Metastatic Breast Cancer
Phase 1
Completed
- Conditions
- Advanced Solid TumorMetastatic Breast Cancer
- Interventions
- First Posted Date
- 2019-05-15
- Last Posted Date
- 2024-12-31
- Lead Sponsor
- Orinove, Inc.
- Target Recruit Count
- 58
- Registration Number
- NCT03950570
- Locations
- 🇺🇸
University of California Irvine Medical Center (UCIMC) - Chao Family Comprehensive Cancer Center, Orange, California, United States
🇺🇸University of California Los Angeles (UCLA) - Jonsson Comprehensive Cancer Center (JCCC) - Oncology Center - Westwood, Westwood, California, United States
🇺🇸University of Colorado Anschutz Medical Campus, Denver, Colorado, United States
© Copyright 2025. All Rights Reserved by MedPath